The company's advanced genetic immunization strategies are applicable in multiple species, including transgenics and across all discovery platforms, it said.
There is growing demand for therapeutic antibodies against challenging, conformation-sensitive drug targets.
Genetic immunization overcomes the obstacles of difficult antigens making it an ideal immunization platform in therapeutic discovery campaigns.
Immunoprecise also announced Monday that it had settled $1.37 million of previously issued debentures by issuing 1.37 million units at a price of $1 per unit.
The purpose of the debt settlement is to shore up Immunoprecise's balance sheet by removing continuing debt obligations related to $1,377,000 of debentures
Shares in Toronto eased 1.2% to $0.77.